{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:54:47Z","timestamp":1765961687836,"version":"3.40.5"},"reference-count":22,"publisher":"PAGEPress Publications","issue":"3","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Histochem"],"abstract":"<jats:p>This study aimed at exploring the expression and clinical significance of aromatase P450, adhesion molecule CD24 and HER2\/neu in endometrial cancer. The expression of aromatase P450, adhesion molecule CD24 and HER2\/neu was detected by immunohistochemistry in 15 cases of endometrial hyperplasia group, 50 cases of endometrial adenocarcinoma and 3 cases of uterine papillary adenocarcinoma, with 15 cases of normal endometrium as control group. We detected no expression of aromatase P450, adhesion molecule CD24 or HER2\/neu in control group. Aromatase P450 positive expression rate was 66.7% in endometrial hyperplasia group and 70.3% in endometrial carcinoma group, without significant difference (p&gt;0.05). There was no significant difference (p&gt;0.05) in the positive expression rate of aromatase P450 between different myometrial invasion groups of endometrial adenocarcinomas. CD24 positive expression rate was 40.0% in endometrial hyperplasia group and 79.6% in endometrial carcinoma group, with significant difference (p&lt;0.05). HER2\/neu positive expression rate was 26.7% in the endometrial hyperplasia group and 57% in endometrial carcinoma group, with significant difference (p&lt;0.05). In conclusion, aromatase P450 may be one factor associated with endometrial cancer cell proliferation, while CD24 and HER2\/neu may be important factors associated with the invasion and metastasis of endometrial cancer.<\/jats:p>","DOI":"10.4081\/ejh.2023.3655","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T08:08:01Z","timestamp":1691654881000},"source":"Crossref","is-referenced-by-count":3,"title":["Expression and clinical significance of HER2\/neu, aromatase P450 and adhesion molecule CD24 in endometrial cancer"],"prefix":"10.4081","volume":"67","author":[{"given":"Liyun","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-0502","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"23870","doi-asserted-by":"crossref","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Nat Cancer Center 2022;2:1-9.","DOI":"10.1016\/j.jncc.2022.02.002"},{"key":"23871","doi-asserted-by":"crossref","unstructured":"Yang X, Ma K, Chen R, Zhang N, Meng Y, Wen J, et al. Immunocytochemical examination of PTEN and Ki-67 for endometrial carcinoma using thin-layer endometrial preparations. Biocell 2021;45:923-32.","DOI":"10.32604\/biocell.2021.013625"},{"key":"23872","doi-asserted-by":"crossref","unstructured":"Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem 2002;80:203-12.","DOI":"10.1016\/S0960-0760(01)00187-X"},{"key":"23873","doi-asserted-by":"crossref","unstructured":"Brodie AMH, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, et al. Aromatase and COX-2 expression in human breast cancers. J. Steroid Biochem 2001;79:41-7.","DOI":"10.1016\/S0960-0760(01)00131-5"},{"key":"23874","doi-asserted-by":"crossref","unstructured":"Kaipparettu BA, Malik S, Konduri SD, Liu W, Rokavec M, Van Der Kuip H, et al. Estrogen-mediated downregulation of CD24 in breast cancer cells. Int J Cancer 2008;123:66-72.","DOI":"10.1002\/ijc.23480"},{"key":"23875","doi-asserted-by":"crossref","unstructured":"Altevogt P, Sammar M, H\u00fcser L, Kristiansen G. Novel insights into the function of CD24: A driving force in cancer. Int J Cancer 2021;148:546-59.","DOI":"10.1002\/ijc.33249"},{"key":"23876","doi-asserted-by":"crossref","unstructured":"Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2\/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007;19:56-62.","DOI":"10.1097\/GCO.0b013e328012980a"},{"key":"23877","doi-asserted-by":"crossref","unstructured":"Buza N, Roque DM, Santin AD. HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 2014;138:343-50.","DOI":"10.5858\/arpa.2012-0416-RA"},{"key":"23878","doi-asserted-by":"crossref","unstructured":"Gardella B, Dominoni M, Bogliolo S, Cassani C, Carletti GV, De Silvestri A, et al. Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women? BMC Palliat Care 2021;20:28.","DOI":"10.1186\/s12904-021-00719-0"},{"key":"23879","doi-asserted-by":"crossref","unstructured":"Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003;129:245-9.","DOI":"10.1007\/s00432-003-0427-9"},{"key":"23880","doi-asserted-by":"crossref","unstructured":"Carreau S, Bourguiba S, Lambard S, Galeraud-Denis I, Genissel C, Levallet J. Reproductive system: aromatase and estrogens. Mol Cell Endocrinol 2002;193:137-43.","DOI":"10.1016\/S0303-7207(02)00107-7"},{"key":"23881","doi-asserted-by":"crossref","unstructured":"Qian B, Huang Y, Qiu Z, Ying X, Yang G, Li H, et al. Tet methylcytosine dioxygenase 2 suppresses renal cell cancer proliferation and metastasis by regulating the miR-200c-SCD axis. Biocell 2021;45:599-615.","DOI":"10.32604\/biocell.2021.014633"},{"key":"23882","doi-asserted-by":"crossref","unstructured":"Lin CY, Tsai CL, Chao A, Lee LY, Chen WC, Tang YH, et al. Nucleophosmin\/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression. J Mol Med (Berl) 2021;99:1125-37.","DOI":"10.1007\/s00109-021-02079-x"},{"key":"23883","doi-asserted-by":"crossref","unstructured":"Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2\/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 2004;95:570-5.","DOI":"10.1016\/j.ygyno.2004.08.043"},{"key":"23884","doi-asserted-by":"crossref","unstructured":"Wang X, Yue J, Kang Y, Dai Z, Ju J, Wang J, et al. Combined chemo-endocrine therapy as a potential new option for HR+\/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine. Cancer Biol Med 2023;20:287-96.","DOI":"10.20892\/j.issn.2095-3941.2022.0702"},{"key":"23885","doi-asserted-by":"crossref","unstructured":"Han S, Park S, An J, Yang J-Y, Chung J-W, Kim YJ, et al. HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer. Sci Rep 2020;10:5270.","DOI":"10.1038\/s41598-020-61567-1"},{"key":"23886","doi-asserted-by":"crossref","unstructured":"Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, et al. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Lett 2019;461:21-30.","DOI":"10.1016\/j.canlet.2019.06.011"},{"key":"23887","doi-asserted-by":"crossref","unstructured":"Buchynska LG, Brieieva OV, Iurchenko NP. Assessment of HER-2 neu, \u0441-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas. Exp Oncol 2019;41:138-43.","DOI":"10.32471\/exp-oncology.2312-8852.vol-41-no-2.12973"},{"key":"23888","doi-asserted-by":"crossref","unstructured":"Afify AM, Werness BA, Mark HFL. HER-2\/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp Mol Pathol 1999;66:163-9.","DOI":"10.1006\/exmp.1999.2255"},{"key":"23889","unstructured":"Malamou-Mitsi V, Crikoni O, Timotheadou E, Aravantinos G, Vrettou E, Agnantis N, et al. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res 2007;27:1157-65."},{"key":"23890","doi-asserted-by":"crossref","unstructured":"Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2\/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 1993;168:162-9.","DOI":"10.1016\/S0002-9378(12)90907-2"},{"key":"23891","doi-asserted-by":"crossref","unstructured":"Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Nat Cancer Center 2022; 2:277-90.","DOI":"10.1016\/j.jncc.2022.09.002"}],"container-title":["European Journal of Histochemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.ejh.it\/index.php\/ejh\/article\/download\/3655\/3418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejh.it\/index.php\/ejh\/article\/download\/3655\/3418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T08:08:34Z","timestamp":1691654914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejh.it\/index.php\/ejh\/article\/view\/3655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7,26]]}},"URL":"https:\/\/doi.org\/10.4081\/ejh.2023.3655","relation":{},"ISSN":["2038-8306","1121-760X"],"issn-type":[{"type":"electronic","value":"2038-8306"},{"type":"print","value":"1121-760X"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}